Long-Term Follow-Up Data Support Longer RFS with Adjuvant Nivolumab Than with Ipilimumab in Patients with Melanoma at High Risk for Recurrence By Ogkologos - November 5, 2025 164 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 238 Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Addressing Cancer Disparities and New Research in Treating HPV-Positive Head and... March 31, 2022 Genetic Risk Score Increases Prediction of Severe Obesity in Adult Survivors... August 5, 2022 Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 Preguntas frecuentes sobre el COVID-19 y el cáncer: Respuestas para pacientes... June 25, 2020 Load more HOT NEWS Durvalumab Modestly Improves Survival in Advanced Biliary Tract Cancer A Daily Survival Kit for Serious Illness FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer How to Provide Support as a Long-Distance Cancer Caregiver
